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mic, clinical and epidemiological datasets on ever increasing scales
across global populations. Early examples include the international
HapMap project and ongoing efforts include the 1000 Genomes Project,
the genotyping and sequencing of whole populations or signiﬁcant
numbers of national of certain countries. The new initiatives include
the UK10K project (http://www.uk10k.org), which aims to sequence
thousands of genomes in Britain to identify rare variants and produce
a sequence variation resource for future studies, the Qatar Genome Pro-
ject, which will map the genomes of a large group of Qataris to chart a
road map for future treatment through personalized medicine, and
the Estonian Genome Project, which aims to generate data from 70%
of Estonia's population. As a result of the broad sharing and analysis of
these datasets, we are gainingnewknowledge that is sheddingnovel in-
sights into human history and health, such as the patho-biology of some
of the world's most intractable diseases, and strategies for improving
the efﬁcacy and safety of treatments for several global diseases. Open
sharing of data (with public access either directly or via data access
committee, depending on the consent conditions) is thus extremely
important for fully exploiting results and advancing research.
However, to maximize the beneﬁts for the world populations in
terms of improved treatments for genetic disorders that access to geno-
mic data can facilitate,whileminimizing the risks of broad genomic data
sharing, analysis and interpretation, it is important to recognize some
challenges. The major impediments to global data sharing are protec-
tion of participants and technical challenges in accessing data from dis-
parate sources. Here we highlight three issues; ﬁrst, because human
genomic, clinical and epidemiological data can contain very sensitive
information at the individual and population levels, there is a need for
both rigorous institutional ethical review and the implementation of
an informed consent process that protects participants, but at the
same time provides ﬂexibility to use the data for broader research. To
ensure continued participants' protection, data is usually anonymized.
However, if accompanied by enough demographic or phenotypic data,
anonymization is not always 100% effective. In addition, many projects
that have been undertaken did not include broad consent for data shar-
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means.
In most cases, data sits behind data access committees and once ac-
cess is granted, raw or processed ﬁles are made available. However,
some computational experience is usually required to be able to use
the data, namely to mine it or perform meta-analysis. Further, in most
cases technological infrastructure is needed to permit access to speciﬁc
segments of a dataset. The Global Alliance for Genomics and Health
(G4GH: http://genomicsandhealth.org/) initiative is developing Appli-
cation Programming Interfaces (APIs) that will address these types of
requirements and in turn facilitate data sharing across federated re-
sources. These APIs will, for example, enable researchers to compare
variants from different studies or simply to query different sources to
determine whether a variant is present in the dataset or not, without
revealing everything about the data. If more or different data is required
to complete the analysis, further requests are made to the data access
committees. The work of the GA4GH will pioneer a way to enable
more global sharing of publicly accessible genomic data. As part of the
G4GH, the Genomic Data Working Group (http://genomicsandhealth.
org/our-work/working-groups) focuses on data representation, storage,
and analysis, including working with platform development partners
and industry leaders to develop standards that will facilitate interoper-
ability. It works closely with the G4GH Regulatory and Ethics Working
Group to ensure that any data access or sharing complies with ethical
consent associated with the datasets.
Second, the global effort to use genomic approaches to solve human
health problems needs to be more equitable in terms of inclusiveness of
ancestrally diverse study populations. Givenwhat is known about the ex-
istence of population speciﬁc disease genetic variants and the value of
trans-ethnic mapping for discovery, replication and ﬁne-mapping, it is a
scientiﬁc imperative that genomics becomes more globally diverse. Cur-
rently, over 90% of all GWAS focused on people of European ancestry,
leaving the promise of genomic science unlikely to be realized in a timely
and efﬁcient manner for all human populations. With the funding of
major international initiatives, such as the Human Heredity and Health
in Africa (H3Africa)1 and the establishment of the Mexico National Insti-
tute of Genomic Medicine (INMEGEN), the global community is begin-
ning to address this problem. With over $70 M multiple year
commitment from the NIH and the Wellcome Trust, H3Africa is creating
and supporting a pan-continental network of labs, bioinformatics and1 Rotimi C., et al. H3Africa Consortium. Research capacity. Enabling the genomic revolu-
tion in Africa. Science. 2014 Jun 20;344(6190):1346-8.
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demiologic approaches to study the genetic and environmental bases of
disease susceptibility and drug responses in Africans. H3Africa is already
changing the landscape of genomic research in Africa.1 INMEGEN was
established by the Mexican congress in 2004 as a means of ﬁnding new
strategies to tackle common diseases. This effort which includes the con-
struction of a haplotype map of the Mexican populations and the devel-
opment of large genetic epidemiology projects for the study of common
diseases and biomarker discovery is beginning to provide novel insights
into the history and health of the Mexican people. We strongly advocate
for the expansion of these global efforts in low resourced nationswith the
goal of establishing state-of-the-art genomic infrastructure and training.
We envision that this goal can be achieved by ﬁrst understanding the po-
litical, economic and scientiﬁc expertise needed across national and inter-
national interest groups including local government agencies, private
biomedical funding agencies, healthcare providers, biotechnology com-
panies and advocacy groups among others. Second, trusted partnership
with the strongest ethics and privacy requirements must be developed.
Third, these partnerships must acknowledge and be willing to work to
overcome the challenges of some its members such that these global
arrangements are not perceived simply as a way to make valuable geno-
mic and clinical data available to scientists in the industrialized nations. If
concerns are addressed properly, it is indeed possible that these global
collaborationswill ensure the full participation of ancestrally diverse pop-
ulations in genomic science as scientists and study participants with the
ultimate goal of avoiding the exacerbation of current inequities in health
and lack of diversity in biomedical research.
Lastly, we advocate for global data and knowledge sharing policies
that recognize the strengths and challenges of scientists in different eco-
nomic and cultural settings. The process of generating genetic epidemi-
ology datasets usually requires costly investment of time and effort on
the part of several scientists. In this regard, it is important to derive as
much beneﬁt as possible, in terms of publications and training of stu-
dents in genomics and other aspects of biomedical research. However,
this should not be at the expense of global data sharing. To ensurethat the efforts of scientists generating the original data are adequately
recognized, it is important that they have the necessary infrastructure
and scientiﬁc capacity to take a timely advantage of the data that they
have generated. Achieving this goal may be problematic for young or
new investigators to the ﬁeld of genomics and in general for scientists
from developing countries who do not have access to extensive re-
sources available to some researchers in the developed world. This
highlights the need to accelerate the training of these investigators
and to equip them with the infrastructure required through injection
of funds such as those provided within the H3Africa and other similar
initiatives.
Lack of access to skills and infrastructure would lengthen the time
for researchers to achieve their research objectives, and if their data
becomes publicly accessible too soon, they will lose the opportunity to
be ﬁrst to publish on the data. Processing of large volumes of genomic
data, for example, will take much longer where computing resources
are limited, and even transferring the data from the site of generation
(e.g. sequencing centers) to the site of analysis is a major challenge in
developing countries due to poor internet connectivity. This can be ad-
dressed by publication embargo policy that recognizes these limitations
by providing relatively long time to publish their papers before making
the datasets publicly available. A recent example is the data sharing
policy of the H3Africa initiative available at www.h3africa.org. The
H3Africa consortium data sharing and access policy provides for an ex-
tended time period for analysis prior to submission to public reposito-
ries. Concessions by funding agencies that take into account available
resources of groups they fundwill be important for protecting the inter-
ests of these groups, but ultimately, the data should be shared to enable
others to beneﬁt from the data and to use it for the advancement of
science, economy and health of global populations. In all, data sharing
across national and institutional boundaries is good for science and for
the creation of “global good”. However, sharing has to be done ethically
and fairly with a clear process of community engagement when appro-
priate and a robust process of obtaining individual informed consent for
both primary and secondary uses of generated data.
